MarketInOut Stock Screener Log In | Sign Up
 

Apollomics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/18/2026
Apollomics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization64.44 mln
Float1.83 mln
Earnings Date12/22/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

7 / 100
Severely lagging

Pre-Tax Margin

-129%
Severely loss-making

ROE

-1,305
Deeply negative

Altman Z-Score

-148
Deeply distressed

ROA

-106
Deeply negative

Business Description

Apollomics is a drug development company focused on finding new treatments for cancer. Founded in 2015 and based in Foster City, California, the company is currently testing several experimental medicines in clinical trials, targeting the biological signals that allow cancer cells to grow and spread. Its most advanced candidate, Vebreltinib, is in Phase 2 trials for lung cancer and other solid tumors, while additional treatments targeting brain cancer and other tumor types are in earlier stages of testing.

Key Fundamentals

EPS-7.57
ROE-1,305
RPS6.11
ROIC-538
ROA-106
Interest Cover-146
EBITDA, mln-10.62
EV / EBITDA-7.01
EV / EBIT-6.84
Revenue, mln8.50
EV / Revenue8.75

Quote Details

Last 23.42
Change 0.89 (3.95%)
Open 22.50
Volume 5,857
Turnover 137,171
Average Volume 8,219.62

Financial Ratios

Pre-Tax Profit Margin-129
Current Ratio0.96
Price / Sales3.45

Financial Strength

Altman Z-Score-148
Piotroski F-Score 4 / 9
Short Ratio0.27
Short % of Float0.41

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.9% 77 / 100   
1 Month -0.72% 59 / 100   
2 Months 69.83% 98 / 100   
6 Months 17.69% 77 / 100   
1 Year 296% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us